Delcath Systems (DCTH) Competitors $12.24 -0.45 (-3.55%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$12.24 -0.01 (-0.04%) As of 07/7/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DCTH vs. LMAT, EYE, ENOV, CNMD, AORT, CDRE, TNDM, ESTA, LQDA, and SSIIShould you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), Liquidia Technologies (LQDA), and SS Innovations International (SSII). These companies are all part of the "medical equipment" industry. Delcath Systems vs. Its Competitors LeMaitre Vascular National Vision Enovis CONMED Artivion Cadre Tandem Diabetes Care Establishment Labs Liquidia Technologies SS Innovations International Delcath Systems (NASDAQ:DCTH) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Which has more volatility & risk, DCTH or LMAT? Delcath Systems has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Is DCTH or LMAT more profitable? LeMaitre Vascular has a net margin of 19.96% compared to Delcath Systems' net margin of -26.38%. LeMaitre Vascular's return on equity of 13.53% beat Delcath Systems' return on equity.Company Net Margins Return on Equity Return on Assets Delcath Systems-26.38% -29.44% -20.75% LeMaitre Vascular 19.96%13.53%9.78% Does the media refer more to DCTH or LMAT? In the previous week, Delcath Systems had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 2 mentions for Delcath Systems and 0 mentions for LeMaitre Vascular. Delcath Systems' average media sentiment score of 0.03 beat LeMaitre Vascular's score of 0.00 indicating that Delcath Systems is being referred to more favorably in the media. Company Overall Sentiment Delcath Systems Neutral LeMaitre Vascular Neutral Do institutionals and insiders believe in DCTH or LMAT? 61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 9.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, DCTH or LMAT? LeMaitre Vascular has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDelcath Systems$37.21M11.46-$26.39M-$0.50-24.48LeMaitre Vascular$226.26M8.29$44.04M$1.9841.91 Do analysts prefer DCTH or LMAT? Delcath Systems currently has a consensus price target of $24.00, indicating a potential upside of 96.08%. LeMaitre Vascular has a consensus price target of $97.83, indicating a potential upside of 17.90%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts clearly believe Delcath Systems is more favorable than LeMaitre Vascular.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00LeMaitre Vascular 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryDelcath Systems and LeMaitre Vascular tied by winning 8 of the 16 factors compared between the two stocks. Get Delcath Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DCTH vs. The Competition Export to ExcelMetricDelcath SystemsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$441.94M$6.86B$5.52B$9.02BDividend YieldN/A1.21%5.24%4.08%P/E Ratio-24.4825.5527.1920.04Price / Sales11.46111.05413.81108.84Price / CashN/A21.4826.2128.59Price / Book5.694.727.925.55Net Income-$26.39M$173.18M$3.17B$248.49M7 Day Performance-4.08%0.34%1.78%4.87%1 Month Performance-25.27%-2.74%1.26%6.63%1 Year Performance54.74%25.56%33.30%20.38% Delcath Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DCTHDelcath Systems3.2332 of 5 stars$12.24-3.5%$24.00+96.1%+53.8%$441.94M$37.21M-24.4860Analyst DowngradeLMATLeMaitre Vascular2.398 of 5 stars$83.05+0.6%$97.83+17.8%-0.2%$1.87B$219.86M41.94490EYENational Vision2.4116 of 5 stars$23.01-0.7%$18.67-18.9%+90.3%$1.83B$1.82B-69.7313,411ENOVEnovis3.5369 of 5 stars$31.36-1.3%$58.00+84.9%-26.3%$1.82B$2.11B-2.257,367Positive NewsCNMDCONMED4.6269 of 5 stars$52.10-0.1%$62.20+19.4%-24.7%$1.61B$1.31B13.713,900News CoverageAORTArtivion2.7451 of 5 stars$31.17-0.1%$32.00+2.7%+19.6%$1.33B$388.54M-62.341,600CDRECadre3.5274 of 5 stars$31.94-0.3%$37.50+17.4%-8.1%$1.30B$567.56M33.622,284TNDMTandem Diabetes Care4.2741 of 5 stars$18.64-1.6%$33.43+79.3%-59.8%$1.26B$940.20M-6.712,650Positive NewsESTAEstablishment Labs1.1995 of 5 stars$42.71+4.3%$52.40+22.7%+6.7%$1.18B$166.02M-13.781,018LQDALiquidia Technologies3.2022 of 5 stars$12.46-4.9%$26.89+115.8%+1.8%$1.12B$14M-7.8950SSIISS Innovations InternationalN/A$5.89+2.1%N/AN/A$1.12B$20.65M0.004Positive News Related Companies and Tools Related Companies LeMaitre Vascular Competitors National Vision Competitors Enovis Competitors CONMED Competitors Artivion Competitors Cadre Competitors Tandem Diabetes Care Competitors Establishment Labs Competitors Liquidia Technologies Competitors SS Innovations International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DCTH) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
